Nephrologists should prioritize routine screening for metabolic markers including uric acid level, lipid profile, and inflammatory biomarkers (CRP, IL-6, TNF-α) in patients with early-stage CKD or those at risk of CKD. This evidence concerns the gene IL6 and chronic kidney disease.